Raymond Miller, M.Sc., D.Sc.

Raymond Miller

Senior Scientific Advisor

Pharmaceutics

OFFICE: 6550 Sanger Road, Office 471, Orlando FL 32827

EMAIL: raymond.miller@cop.ufl.edu

PHONE: 407-313-7032

CV: Link to CV

 

Education

  • Diploma in Clinical Pharmacology, University of California, San Francisco, CA, 1997
  • D.Sc. in Pharmacology, University of Potchefstroom, South Africa, 1974
  • M.Sc. in Pharmacology, University of Potchefstroom, South Africa, 1971
  • B.Sc. in Pharmacy and Chemistry, University of Potchefstroom, South Africa, 1968

Biographical Sketch

Raymond Miller, M.Sc., D.Sc., currently serves as senior scientific advisor at the Center for Pharmacometrics & Systems Pharmacology at the University of Florida Research and Academic Center. He is responsible for providing scientific research leadership and strategic expertise in support of the faculty, post-doctoral research associates and Ph.D. candidates in the center. He received his B.Sc. Pharmacy, M.Sc and D.Sc. degrees from the University of Potchefstroom, South Africa. He then spent two years as a clinical pharmacology fellow at the University of California, San Francisco. He served as professor and chairman of the Department of Pharmacology, University of Durban-Westville, South Africa for a period of 10 years. He joined the Food and Drug Administration as a pharmacometrician in the Office of Clinical Pharmacology and Biopharmaceutics for a period of five years. In 1999 he joined Parke Davis/Pfizer, Ann Arbor where he was instrumental in building and leading the pharmacometrics group over a period of eight years. He spent an additional two years at New London Pfizer in pharmacometrics. He served as Executive Director, Modeling and Simulation at Daiichi Sankyo Pharma Development for six years as global lead in pharmacometrics. At Daiichi, he directed the pharmacometric activities for the filing of edoxaban for stroke prevention. He was co-recipient of the 2008 AAPS Outstanding Manuscript in Modeling and Simulation award for the paper describing a longitudinal exposure-adverse event relationship. He served on the organizing committee for the 2009 DIA/FDA/PhRMA conference on modeling and simulation and on the organizing committee for the 2008 and 2009 American Conference on Pharmacometrics (ACOP). He was a founding member of the International Society of Pharmacometrics (ISOP). He served on the faculty of the NIH department of Clinical Pharmacology over a period of ten years.

Affiliations

  • American Society for Clinical Pharmacology and Therapeutics
  • American Association of Pharmaceutical Scientists
  • Academy of Pharmaceutical Sciences
  • Boehringer Bursary, South African Pharmacological Society
  • South African Medical Research Council

Select Publications

Nyberg J, Karlsson K, Jönsson S, Yin QP, Miller R, Karlsson MO, Simonsson USH. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. Pharmacometrics & Systems Pharmacology, 2016, 5, 222–232.

Krekels EHJ, Niebecker R, Karlsson MO, Miller R, Shimizu T, Karlsson KE, Ruff CT, Simonsson USH, Jönsson S. Population Pharmacokinetics of Edoxaban in patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial. Clin Pharmacokinet, 2016, 55 (9), 1079–1090.

Yin, QP; Merante D; Truitt K; Miller R. Population Pharmacokinetic Modeling and Simulation for Assessing Renal Impairment Effect on the Pharmacokinetics of Mirogabalin. J Clin Pharmacol. 2016 Feb;56(2):203-12.

Hutmacher MM, Frame B, Miller R, Truitt K, Merante D. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. J Clin Pharmacol. 2016 Jan;56(1):67-77.